A GUIDE FOR **RADICAVA ORS® PATIENTS**

Understand treatment and help slow the loss of physical function

INDICATION

RADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

IMPORTANT SAFETY INFORMATION

Do not receive RADICAVA ORS® (edaravone) if you are allergic to edaravone or any of the ingredients in RADICAVA ORS.

Please see the full Prescribing Information and Patient Information, also available at www.radicavaors.com.

Radicava ORS® (edaravone) Oral Suspension 105mg/5mL

The importance of managing ALS

Although there are no known treatments that cure or reverse amyotrophic lateral sclerosis (ALS), RADICAVA ORS® (edaravone) can make a difference in helping to slow the loss of physical function, and offers the same drug as RADICAVA® (edaravone) in an oral formulation.

ALS continues to progress, which can make it hard to know if treatment is helping. The ALS Functional Rating Scale–Revised (ALSFRS-R) measures how you are doing now and will help track disease progression. It consists of 4 categories that add up to a total of 48 points. In addition to treatment with RADICAVA ORS®, talk to your doctor about other ways to help slow your progression or adapt to overcome functional losses over time.

Points represent physical function

Decline on the ALSFRS-R may vary widely among those with ALS. Some can lose 0 to 1 point per month while others may lose up to 6 points per month.



Losing or keeping a single point on the ALSFRS-R can have a significant impact on those living with ALS.

Even though you might not feel a change, being on RADICAVA ORS® is an important step that may help slow the loss of physical function over time.

IMPORTANT SAFETY INFORMATION

Before you take RADICAVA ORS, tell your healthcare provider about all of your medical conditions, including if you:

- have asthma.
- are allergic to other medicines.
- are pregnant or plan to become pregnant. It is not known if RADICAVA ORS will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if RADICAVA ORS passes into your breastmilk. You and your healthcare provider should decide if you will receive RADICAVA ORS or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see the full Prescribing Information and Patient Information, also available at www.radicavaors.com.

Radicava ORS® (edaravone) Oral Suspension 105mg/5mL

RADICAVA® was evaluated in a phase 3 clinical study

In ALS, every point matters

On the ALSFRS-R, the more points preserved, the greater the physical function. In the pivotal clinical study, patients taking RADICAVA® (edaravone) lost an average of 2.49 fewer points vs those taking placebo who declined more rapidly at 24 weeks.

RADICAVA slowed the loss of physical function vs placebo at 24 weeks.



2.49-fewer points lost on average on the ALSFRS-R with RADICAVA

This represents

33% less decline in physical function

Individual results may vary.

A change in slope of the ALSFRS-R of 20% to 25% or greater is considered clinically meaningful according to the Northeast ALS Consortium (NEALS).[a]

RADICAVA ORS® is generally well tolerated

- The safety profile of RADICAVA was evaluated in multiple placebo-controlled studies of 184 patients with ALS
- RADICAVA ORS® (edaravone) was generally well tolerated in a 6-month clinical study of 185 patients with ALS

The most common side effects for patients taking RADICAVA were bruising (contusion) [15%], problems with walking (gait disturbance) [13%], and headache [10%]. Fatigue was also reported in 7.6% of patients taking RADICAVA ORS®.

These are not all of the possible side effects with RADICAVA or RADICAVA ORS®.

[a]Based on a report surveying 65 NEALS members.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of RADICAVA ORS?

RADICAVA ORS may cause serious side effects, including hypersensitivity (allergic) reactions and sulfite allergic reactions.

- Hypersensitivity reactions have happened in people taking RADICAVA ORS and can happen after your medicine has been taken.

Please see the full Prescribing Information and Patient Information, also available at www.radicavaors.com.

Radicava ORS® (edaravone) Oral Suspension 105mg/5mL

The impact of RADICAVA ORS® on patients

In 2024, the FDA recognized RADICAVA ORS® (edaravone) as a **major contribution to patient care**.

This is due to its oral suspension route of administration that provides a less burdensome option vs IV administration of previously approved RADICAVA® (edaravone).

Not actual size.

FDA=Food and Drug Administration; IV=intravenous.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of RADICAVA ORS? *(continued)*

- RADICAVA ORS contains sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe asthma episodes in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma.
- Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: hives; swelling of the lips, tongue, or face; fainting; breathing problems; wheezing; trouble swallowing; dizziness; itching; or an asthma attack (in people with asthma).

Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects and allergic reactions.

The most common side effects of RADICAVA® (edaravone) and RADICAVA ORS include bruising (contusion), problems walking (gait disturbance), and headache.

Please see the full Prescribing Information and Patient Information, also available at www.radicavaors.com.

RADICAVA ORS® has a foundation of clinical and real-world experience

RADICAVA ORS® (edaravone) is an oral formulation of RADICAVA® (edaravone)—a proven therapy evaluated in over 2 decades of clinical research, including 4 phase 3 clinical trials.

Since 2017

7+

years of RADICAVA experience since FDA approval.

~600

people have taken part in multiple clinical studies that have established the safety and tolerability of RADICAVA

10,600+

people have been treated with RADICAVA ORS®[a]



997,400+

days of therapy[b]

For more about the clinical history of RADICAVA ORS®, visit **RADICAVASolidGround.com**

[a]Based on RADICAVA ORS® prescriptions submitted in the US as of August 2024. Not independently verified.
[b]Days of therapy based on number of RADICAVA ORS® cartons sold as of September 2024. For RADICAVA ORS®, each Starter Kit includes 14 days of therapy, and each Maintenance Kit includes 10 days of therapy.

IMPORTANT SAFETY INFORMATION

These are not all the possible side effects of RADICAVA and RADICAVA ORS. **Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to www.fda.gov/medwatch or Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058.**

Please see the full Prescribing Information and Patient Information, also available at www.radicavaors.com.

Radicava ORS® (edaravone) Oral Suspension 105mg/5mL

JourneyMate SUPPORT PROGRAM™

Dedicated Team. Patient-Focused Approach.

A patient-focused approach to ALS and treatment support

No matter where you are in your ALS and RADICAVA ORS® (edaravone) journey, the ***JourneyMate Support Program***™ gives you the understanding, personalized answers, and resources to help you move forward. Experienced program team members are trained to address your educational needs as you continue treatment and provide you with personalized answers and resources for living with ALS. Call the ***JourneyMate Support Program***™ or visit radicavaors.com.[a] This program is here to supplement the resources that your doctor provides.

Have questions about ALS or your RADICAVA ORS® treatment?

Call a JourneyMate Resource Specialist—your go-to resource in the ***JourneyMate Support Program***™—at 1-855-457-6968 from 9 AM to 9 PM ET, Monday through Friday.

Some patients with commercial health insurance may be eligible for an Out-of-Pocket Assistance Program to help save on out-of-pocket costs for your RADICAVA ORS® prescription.[b]

Annual re-enrollment, available upon re-verification of commercial insurance benefits will confirm your continued eligibility for the Out-of-Pocket Assistance Program.

A JourneyMate Resource Specialist discusses basic information about Mitsubishi Tanabe Pharma America, Inc. products and does not take the place of a patient's doctor. Patients should be sure to talk to their doctor about all treatment-related questions, as their doctor is the best person to help a patient decide if treatment is right for them. If a patient has a medical emergency, they should call 911. Adverse events or product complaints should be reported by calling 1-888-292-0058.

[a]Read the Instructions for Use before you take RADICAVA ORS®.

[b]This is not insurance. This offer is for eligible patients who have private, commercial health insurance with prescription coverage for RADICAVA ORS®. Patients enrolled in commercial prescription drug insurance and Medicare Part A and/or Part B are eligible for assistance so long as they meet all other eligibility criteria and are not enrolled in or become enrolled in Medicare Parts C or D. Support is not valid for patients covered, in whole or in part, by Medicaid, Department of Veterans Affairs (VA), Department of Defense (DoD), or any other federal or state health insurance program. Annual maximum benefit per patient. Additional terms and conditions apply. See full Eligibility Requirements & Terms and Conditions at RadicavaOOP.com.

Mitsubishi Tanabe Pharma America

Radicava ORS® (edaravone) Oral Suspension 105mg/5mL